Duerinck, Johnny and Du Four, Stephanie and Sander, Wilhelm and Van Binst, Anne-Marie and Everaert, Hendrik and Michotte, Alex and Hau, Peter and Neyns, Bart (2015) Sunitinib Malate plus Lomustine for Patients with Temozolomide-refractory Recurrent Anaplastic or Low-grade Glioma. ANTICANCER RESEARCH, 35 (10). pp. 5551-5557. ISSN 0250-7005, 1791-7530
Full text not available from this repository. (Request a copy)Abstract
Tyrosine kinase signaling through the vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor-a (PDGFR-a) and KIT cell surface receptors mediates neo-angiogenesis and contributes to cancer cell survival in recurrent anaplastic and low-grade glioma. Thirteen patients with temozolomide-refractory recurrent anaplastic or low-grade glioma were treated with sunitinib malate, a small-molecule tyrosine kinase inhibitor of the VEGFR, PDGFR, and KIT receptors, in combination with lomustine. The most frequent grade 3 and 4 adverse events were fatigue, thrombocytopenia, neutropenia and lymphopenia. The best objective tumor response by Response Assessment in Neuro-Oncology (RANO) criteria was one complete response, one unconfirmed partial response and three cases of stable disease. The median progression-free survival was 1.8 months (95% confidence interval=1.0-2.7 months) with 6-month progression-free survival of 15% (95% confidence interval=0-35%). The median overall survival was 6.7 months (95% confidence interval=0.7-12 months). The investigated combination regimen of sunitinib and lomustine is well-tolerated but insufficiently active to warrant further investigation in an unselected population of patients with temozolomide-refractory recurrent anaplastic and low-grade glioma.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PHASE-II; VINCRISTINE CHEMOTHERAPY; MALIGNANT GLIOMA; OLIGODENDROGLIOMA; PROCARBAZINE; TRIAL; AMPLIFICATION; GLIOBLASTOMA; VEGFR2; CANCER; Sunitinib; lomustine; glioma; recurrent disease |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 06 Jun 2019 11:28 |
| Last Modified: | 06 Jun 2019 11:28 |
| URI: | https://pred.uni-regensburg.de/id/eprint/4760 |
Actions (login required)
 |
View Item |
